A study on the relationship between 18F-FDG PET/CT metabolic parameters and clinicopathological characteristics in patients with non-small cell lung cancer
Objective To investigate the relationship between 18F-FDG PET/CT metabolic parameters and clinicopathological characteristics in patients with non-small cell lung cancer(NSCLC)and evaluate the poten-tial value of these metabolic parameters in the diagnosis and staging of NSCLC.Methods As a retrospective study,this study collected the clinical data of 85 NSCLC patients who underwent 18F-FDG PET/CT examina-tions at our PET/CT center from January 2022 to July 2023.Clinicopathological characteristics including body mass index(BMI),smoking history,pathological type,tumor location,TNM staging,tumor diameter,lymph node metastasis,CYFRA 21-1 expressions,EGFR mutations,and PD-L1 expressions were collected.Medical imaging software was used to analyze 18F-FDG PET/CT metabolic parameters,including SUVmax.MTV,and TLG.The metabolic parameters of patients with different clinicopathological characteristics were compared,and the diagnostic performance of these parameters for disease characteristics was assessed.Re-sults In general characteristics such as BMI and smoking history,there was no statistically significant differ-ence in metabolic parameters between two groups(P＞0.05).The metabolic parameters were significantly different in pathological type,tumor location,TNM stage,tumor diameter,lymph node metastasis,CYFRA 21-1 expressions,EGFR mutation and PD-L1 expression(P＜0.05).SUVmax,MTV,and TLG showed good diagnostic performance in identifying pathological type,TNM staging,tumor diameter,lymph node metasta-sis,EGFR mutations,and PD-L1 expression(AUC=0.7～0.9,P＜0.05).These parameters also showed good diagnostic performance in identifying tumor location and CYFRA 21-1 expressions(AUC=0.6～0.7,P＜0.05).Conclusion 18F-FDG PET/CT metabolic parameters(SUVmax,MTV,and TLG)have potential di-agnostic value for pathological type,staging,tumor diameter,lymph node metastasis,EGFR mutations,and PD-L1 expressions in NSCLC patients.These parameters can provide strong support for personalized treatment and prognostic evaluation of NSCLC.
carcinoma,non-small-cell lung18F-FDG PET/CTmetabolic parameterspathological type
万方数据
